#ESMO20

Stephen V Liu

StephenVLiu

#OncoAlert Available @NEJM, results from the phase III CROWN trial of lorlatinib versus crizotinib as first line treatment for #ALK NSCLC. Initially presented at virtual #ESMO20, lorlatinib had a significantly

Sumanta Pal

montypal

It's Monday AM post-@ASCO #GU21 & clinic starts in a couple of hours! Lots to process - I'll try to tackle optimal 1L tx for #kidneycancer. I'll make a case

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.